Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER3 | P43115 | 2/20 | 0.53 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.53 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.53 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5814319 | 1.00 | PTGER3 (0.53) | PTGER3PTGER4PTGER2PTGER1 | |
| SCHEMBL2241761 | 0.95 | PTGER3 (0.47) | PTGER3PTGER4PTGER2PTGER1 | |
| SCHEMBL12288900 | 0.95 | PTGER3 (0.47) | PTGER3PTGER4PTGER2PTGER1 | |
| SCHEMBL13204793 | 0.92 | PTGER4 (0.43) | PTGER3PTGER4PTGER2 | |
| SCHEMBL5902707 | 0.86 | PTGER4 (0.40) | PTGER3PTGER4PTGER2PTGER1 | |
| SCHEMBL5902794 | 0.85 | PTGER4 (0.39) | PTGER3PTGER4PTGER2PTGER1 | |
| SCHEMBL27629311 | 0.80 | PTGER4 (0.36) | PTGER3PTGER4PTGER2 | |
| SCHEMBL5812669 | 0.80 | PTGER4 (0.76) | PTGER3PTGER4PTGER2 | |
| SCHEMBL6166899 | 0.80 | PTGER4 (0.76) | PTGER3PTGER4PTGER2 | |
| SCHEMBL6158522 | 0.80 | PTGER4 (0.76) | PTGER3PTGER4PTGER2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1503984-B1 | 8-AZAPROSTAGLANDIN ANALOGS AS AGENTS FOR LOWERING INTRAOCULAR PRESSURE | ALLERGAN INC (US) | 2013-03-20 | — | — | EP | claimed |
| US-20040254230-A1 | Method for treating ocular hypertension | MERCK FROSST CANADA LTD. (CA) | 2004-12-16 | — | — | US | claimed |
| EP-1461026-A2 | METHOD FOR TREATING OCULAR HYPERTENSION | Merck & Co., Inc. (US) | 2004-09-29 | — | — | EP | claimed |
| EP-1110949-B1 | EP4 receptor selective agonists in the treatment of osteoporosis | PFIZER PROD INC (US) | 2003-09-24 | — | — | EP | claimed |
| WO-2003047513-A2 | METHOD FOR TREATING OCULAR HYPERTENSION | MERCK & CO., INC. (US) | 2003-06-12 | — | — | WO | claimed |
| US-20020040149-A1 | EP4 receptor selective agonists in the treatment of osteoporosis | CAMERON KIMBERLY O'KEEFE (US) | 2002-04-04 | — | — | US | claimed |
| US-20010047105-A1 | EP4 receptor selective agonists in the treatment of osteoporosis | PFIZER PRODUCTS INC. | 2001-11-29 | — | — | US | claimed |
| WO-2001046140-A1 | EP4 RECEPTOR SELECTIVE AGONISTS IN THE TREATMENT OF OSTEOPOROSIS | PFIZER PRODUCTS INC. (US) | 2001-06-28 | — | — | WO | claimed |
| EP-1110949-A1 | EP4 receptor selective agonists in the treatment of osteoporosis | Pfizer Products Inc. (US) | 2001-06-27 | — | — | EP | claimed |
| EP-1503984-B1 | 8-AZAPROSTAGLANDIN ANALOGS AS AGENTS FOR LOWERING INTRAOCULAR PRESSURE | ALLERGAN INC (US) | 2013-03-20 | — | — | EP | disclosed |
| US-20040254230-A1 | Method for treating ocular hypertension | MERCK FROSST CANADA LTD. (CA) | 2004-12-16 | — | — | US | disclosed |
| EP-1461026-A2 | METHOD FOR TREATING OCULAR HYPERTENSION | Merck & Co., Inc. (US) | 2004-09-29 | — | — | EP | disclosed |
| US-6737437-B2 | FOR EXAMPLE, 7-(2S-(3R-HYDROXY-4-PHENYLBUTYL)-5-OXOPYRROLIDIN -1-YL)HEPTANOIC ACID; PROMOTING BONE READSORPTION; BONE LOSS, FRACTURES, AND DEFECTS; FRAILTY; CHILDHOOD IDIOPATHIC BONE LOSS; ALVEOLAR BONE LOSS, OSTEOTOMY; GUM DISEASE; PROSTHETICS | PFIZER INC. | 2004-05-18 | — | — | US | disclosed |
| US-6642266-B2 | Therapy of condition which presents with low bone mass in a mammal comprising administering to mammal an EP4 (prostaglandins) receptor selective agonist or prodrug | PFIZER INC. | 2003-11-04 | — | — | US | disclosed |
| EP-1110949-B1 | EP4 receptor selective agonists in the treatment of osteoporosis | PFIZER PROD INC (US) | 2003-09-24 | — | — | EP | disclosed |
| WO-2003047513-A2 | METHOD FOR TREATING OCULAR HYPERTENSION | MERCK & CO., INC. (US) | 2003-06-12 | — | — | WO | disclosed |
| US-20020040149-A1 | EP4 receptor selective agonists in the treatment of osteoporosis | CAMERON KIMBERLY O'KEEFE (US) | 2002-04-04 | — | — | US | disclosed |
| US-20010047105-A1 | EP4 receptor selective agonists in the treatment of osteoporosis | PFIZER PRODUCTS INC. | 2001-11-29 | — | — | US | disclosed |
| WO-2001046140-A1 | EP4 RECEPTOR SELECTIVE AGONISTS IN THE TREATMENT OF OSTEOPOROSIS | PFIZER PRODUCTS INC. (US) | 2001-06-28 | — | — | WO | disclosed |
| EP-1110949-A1 | EP4 receptor selective agonists in the treatment of osteoporosis | Pfizer Products Inc. (US) | 2001-06-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020040149-A1 | EP4 receptor selective agonists in the treatment of osteoporosis | PTGER4, PTGER1, PTGER2 | PTGER3 4/4885PTGER4 1/4885PTGER2 3/4885 |
| US-20010047105-A1 | EP4 receptor selective agonists in the treatment of osteoporosis | PTGER4, PTGER1, PTGER2 | PTGER3 4/4885PTGER4 1/4885PTGER2 3/4885 |
| US-20040254230-A1 | Method for treating ocular hypertension | PTGIR, PTGER4, PTGER1 | PTGER3 5/4885PTGER4 2/4885PTGER2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.